Accenture finds holiday shoppers spending more, turning to AI
The survey of 4,048 U.S. shoppers found that average holiday spending is expected to reach $737 per consumer in 2026, nearly 12% higher than last year.
The survey of 4,048 U.S. shoppers found that average holiday spending is expected to reach $737 per consumer in 2026, nearly 12% higher than last year.
About half of consumers (49%) said they plan to begin shopping for Halloween in September or earlier.
Modern oral-care brand brings innovative, wellness-driven products to consumers nationwide.
Walgreens said the new location is expected to play an important role in the neighborhood.
Apple Cinnamon and Winter Woods scents available through December 2026.
Aims to connect older adults with health and wellness resources.
Neutrogena is expanding its sun care lineup with two facial sunscreens featuring the newly approved BEMT UV filter.
NFL legend and longtime broadcaster joins Particle to promote simple, effective personal care for men.
The new offering includes DirectAccess, a direct-to-consumer option that provides eligible members access to GLP-1 medications for weight management outside the traditional pharmacy benefit.
The program includes upfront GLP-1 costs and an option for on-demand care—increasing patient access and choice for weight loss care.
Under the theme “Retail and Beyond,” executives provided investors with an update on the company's strategy, operating priorities and growth opportunities.
First-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needs.
E-commerce holiday sales projected to reach $316.1 billion to $318.9 billion, increasing 7.5% to 8.4%.
As beards make their seasonal return, Wahl offers versatile grooming solutions designed to keep every look sharp, sculpted and intentional.
New study reveals many U.S. adults still face barriers to preventive health screenings.
A first-of-its-kind, non-opioid OTC option for the millions managing persistent pain, is backed by more than a decade of research, including Phase 3 data to be presented at PAINWeek.